- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07441694
Studie av INCA036978 hos deltakere med myeloproliferative neoplasi
En fase 1, åpen, multikenterstudie av INCA036978 hos deltakere med myeloproliferative neoplasi
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Incyte Corporation Call Center (US)
- Telefonnummer: 1.855.463.3463
- E-post: medinfo@incyte.com
Studer Kontakt Backup
- Navn: Incyte Corporation Call Center (ex-US)
- Telefonnummer: +800 00027423
- E-post: eumedinfo@incyte.com
Studiesteder
-
-
New South Wales
-
Concord, New South Wales, Australia, 02139
- Rekruttering
- Concord General Repatriation Hospital
-
St Leonards, New South Wales, Australia, 02065
- Rekruttering
- Royal North Shore Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australia, 04066
- Rekruttering
- Icon Cancer Centre
-
-
Victoria
-
East Melbourne, Victoria, Australia, 03002
- Rekruttering
- Epworth Health Care
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 06009
- Rekruttering
- Linear Clinical Research
-
-
-
-
-
Liège, Belgia, 04000
- Har ikke rekruttert ennå
- Centre Hospitalier Universitaire (Chu) de Liege
-
Roeselare, Belgia, 08800
- Har ikke rekruttert ennå
- AZ DELTA
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Har ikke rekruttert ennå
- McGill University Jewish General Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Har ikke rekruttert ennå
- University of Alabama At Birmingham
-
-
California
-
Irvine, California, Forente stater, 92618
- Rekruttering
- City of Hope-Lennar Foundation Cancer Center
-
Los Angeles, California, Forente stater, 90095
- Har ikke rekruttert ennå
- UCLA Medical Hematology & Oncology
-
Los Angeles, California, Forente stater, 90033
- Har ikke rekruttert ennå
- Usc Norris Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Har ikke rekruttert ennå
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Har ikke rekruttert ennå
- University of Miami
-
Tampa, Florida, Forente stater, 33612
- Har ikke rekruttert ennå
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Winship Cancer Institute of Emory University
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Har ikke rekruttert ennå
- John Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63108
- Har ikke rekruttert ennå
- Washington University School of Medicine
-
-
New York
-
New York, New York, Forente stater, 10065
- Har ikke rekruttert ennå
- Weill Cornell Medicine
-
New York, New York, Forente stater, 10029
- Har ikke rekruttert ennå
- Mount Sinai School of Medicine
-
New York, New York, Forente stater, 10021
- Har ikke rekruttert ennå
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, Forente stater, 28204
- Har ikke rekruttert ennå
- Levine Cancer Institute
-
Durham, North Carolina, Forente stater, 27705
- Har ikke rekruttert ennå
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Har ikke rekruttert ennå
- Cleveland Clinic
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tristar Bmt/Tcto
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Har ikke rekruttert ennå
- University of Texas M. D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Har ikke rekruttert ennå
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Har ikke rekruttert ennå
- Medical College of Wisconsin
-
-
-
-
-
Bordeaux, Frankrike, 33076
- Rekruttering
- Francois-Xavier
-
Paris, Frankrike, 75010
- Rekruttering
- Hospital Saint Louis
-
Villejuif, Frankrike, 94805
- Rekruttering
- Institut Gustave Roussy
-
-
-
-
-
Bologna, Italia, 40138
- Har ikke rekruttert ennå
- Aou Policlinico S. Orsola-Malpighi
-
Milan, Italia, 20122
- Har ikke rekruttert ennå
- Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
-
Roma, Italia, 00168
- Har ikke rekruttert ennå
- A. Gemelli University Hospital, Catholic University of the Sacred Heart
-
Udine, Italia, 33100
- Har ikke rekruttert ennå
- Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
-
-
-
-
-
Kashiwa Chiba, Japan, 277-0882
- Har ikke rekruttert ennå
- National Cancer Center Hospital East
-
Toon, Ehime, Japan, 791-0204
- Har ikke rekruttert ennå
- Ehime University Hospital
-
-
-
-
-
Badalona, Spania, 08916
- Har ikke rekruttert ennå
- Hospital Universitari Germans Trias I Pujol
-
Las Palmas de Gran Canaria, Spania, 35010
- Har ikke rekruttert ennå
- Hospital Universitario de Gran Canaria Dr. Negrin
-
Madrid, Spania, 28041
- Har ikke rekruttert ennå
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, Storbritannia, SE1 9RT
- Har ikke rekruttert ennå
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
Nottingham, Storbritannia, NG5 1PB
- Har ikke rekruttert ennå
- Nottingham University Hospitals
-
Oxford, Storbritannia, OX3 7LE
- Rekruttering
- University of Oxford
-
-
-
-
-
Jongno-gu, Seoul, Sør -Korea, 03080
- Har ikke rekruttert ennå
- Seoul National University Hospital
-
Seocho-gu, Seoul, Sør -Korea, 06591
- Har ikke rekruttert ennå
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Aachen, Tyskland, D-52074
- Rekruttering
- University Medical Center Rwth Aachen
-
Berlin, Tyskland, 10117
- Rekruttering
- Charite Universitaetsmedizin Berlin - Campus Charite Mitte
-
Freiburg im Breisgau, Tyskland, 79106
- Rekruttering
- Universitatklinikum Freiburg
-
Halle, Tyskland, 06120
- Rekruttering
- Universitatsklinikum Halle (Saale)
-
Mainz, Tyskland, 55131
- Har ikke rekruttert ennå
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1a: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. |
|
Eksperimentell: Part 1b: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
|
Eksperimentell: Part 2a: Dose Expansion
INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1 |
INCA036978 will be administered at protocol defined dose. |
|
Eksperimentell: Part 2b: Dose Expansion
INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Tidsramme: Up to 28 days
|
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. |
Up to 28 days
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Up to approximately 2 years
|
Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first. |
Up to approximately 2 years
|
|
Number of participants with TEAEs leading to dose modification or discontinuation
Tidsramme: Up to approximately 2 years
|
Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation. |
Up to approximately 2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics Parameter: Cmax of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as maximum observed plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Tmax of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the time to reach the maximum plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the maximum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the minimum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the area under the concentration-time curve from 0 to infinity of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: CL/F of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent clearance of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Vz/F of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent volume of distribution of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: t1/2 of INCA036978
Tidsramme: Up to approximately 2 years
|
Defined as the apparent terminal phase disposition half-life of INCA036978. |
Up to approximately 2 years
|
|
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Tidsramme: Week 12 and Week 24
|
Defined as percentage of participants with a protocol defined spleen volume reduction. |
Week 12 and Week 24
|
|
For participants with MF and anemia: Anemia Response as defined in the protocol
Tidsramme: Up to approximately 2 years
|
For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol. |
Up to approximately 2 years
|
|
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
|
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Tidsramme: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Incyte Medical Monitor, Incyte Corporation
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Hematologiske sykdommer
- Blodkoagulasjonsforstyrrelser
- Benmargssykdommer
- Hemoragiske lidelser
- Blodplateforstyrrelser
- Benmargsneoplasmer
- Hematologiske neoplasmer
- Hemic og lymfatiske sykdommer
- Trombocytose
- Myeloproliferative lidelser
- Trombocytemi, essensielt
- Polycytemi Vera
- Primær myelofibrose
Andre studie-ID-numre
- INCA036978-101
- 2026-525217-31-00 (Registeridentifikator: EU CT Number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .